Department of Pediatrics, Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, U.S.A; Department of Pediatrics, Northwestern Memorial Feinberg School of Medi-cine, Chicago, Illinois, U.S.A.
Epilepsia. 2015 Jan;56(1):40-8. doi: 10.1111/epi.12862. Epub 2014 Nov 28.
Determine frequency of remissions, relapses, and pharmacoresistance over two decades. Develop a composite measure of seizure control over that time.
Community-based cohort of children with newly diagnosed epilepsy prospectively followed for up to 21 years with frequent calls and periodic medical record review. Multiple periods of 1-, 2-, 3-, and 5-year remission with subsequent relapses were recorded. Other outcomes included pharmacoresistance (failure of two adequately used drugs), early remission and early pharmacoresistance by 2 years, and complete remission at last contact (CR-LC, 5 years both seizure- and drug-free at last contact). A composite summary of seizure course was created with eight categories ranging from early sustained remission and CR-LC (best) to never achieving a 1-year remission (worst).
Five hundred sixteen of 613 participants were followed ≥10 years. An initial 1- 2-, 3-, and 5-year remission occurred, respectively, in 95%, 92%, 89%, and 81%. Relapses followed in 52%, 41%, 29%, and 15%, respectively. Repeated remission after relapse was common. Up to seven 1-year, five 2-year and 3-year, and two 5-year remissions were recorded per participant. Pharmacoresistance at any time, early pharmacoresistance (<2 years), early remission, and CR-LC occurred in 118 (22.9%), 70 (13.6%), 283 (54.8%), and 311 (60.3%). Composite outcomes were early sustained remission with CR-LC (N=172, 33%); later but then sustained remission with CR-LC (N=51, 10%); one (N=61, 12%) or more (N=27, 5%) remission-relapse episodes but then CR-LC; various non-CR-LC outcomes (N=179, 35%); and never achieved 1-year remission (N=26, 5%). These patterns varied across groups defined by epilepsy type and presence of brain insults or neurodisability (p<0.0001).
The seizure prognosis of pediatric epilepsies is highly variable. Most patients follow complex courses not easily summarized by remission status at the end of a period of follow-up. These complexities may facilitate efforts to understand the impact epilepsy has on young people entering adulthood.
在二十年期间确定缓解率、复发率和药物耐药性的频率。制定一个在此期间衡量癫痫发作控制的综合指标。
对新诊断为癫痫的儿童进行基于社区的队列研究,前瞻性随访长达 21 年,通过频繁的电话联系和定期的病历审查进行随访。记录多个 1 年、2 年、3 年和 5 年的缓解期,随后是复发。其他结果包括药物耐药性(两种充分使用的药物治疗失败)、2 年内早期缓解和早期药物耐药性,以及最后一次接触时的完全缓解(CR-LC,5 年无癫痫发作且无药物治疗)。创建了一个综合的癫痫发作病程摘要,共有八个类别,从早期持续缓解和 CR-LC(最佳)到从未达到 1 年缓解(最差)。
516 名参加者中有 613 名随访时间≥10 年。分别有 95%、92%、89%和 81%的患者在初次 1-2-3-5 年缓解,随后分别有 52%、41%、29%和 15%的患者复发。复发后再次缓解较为常见。每个参与者记录了多达 7 个 1 年、5 个 2 年和 3 年以及 2 个 5 年的缓解期。任何时候的药物耐药性、早期药物耐药性(<2 年)、早期缓解和 CR-LC 的发生率分别为 118(22.9%)、70(13.6%)、283(54.8%)和 311(60.3%)。复合结局包括早期持续缓解伴 CR-LC(N=172,33%);随后但持续缓解伴 CR-LC(N=51,10%);1 次(N=61,12%)或更多次(N=27,5%)缓解-复发发作,但随后 CR-LC;各种非 CR-LC 结局(N=179,35%);以及从未达到 1 年缓解(N=26,5%)。这些模式在不同的癫痫类型和是否存在脑损伤或神经功能障碍的分组中存在显著差异(p<0.0001)。
儿科癫痫的癫痫发作预后差异很大。大多数患者的病程复杂,难以用随访结束时的缓解状态简单概括。这些复杂性可能有助于理解癫痫对进入成年期的年轻人的影响。